

20 May 2020

This announcement contains inside information

Renalytix AI plc
("RenalytixAI", the "Company")

Joint venture for scaled production of COVID-19 antibody test kits

Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that its wholly-owned subsidiary, Renalytix AI, Inc. has entered into a joint venture with the Icahn School of Medicine at Mount Sinai ("Mount Sinai"), Kantaro Biosciences, LLC ("Kantaro"), to develop and scale production of COVID-19 antibody test kits.

Highlights

- Mount Sinai and Renalytix AI, Inc. form joint venture, Kantaro, to develop and scale production of covid antibody test kits
- Kantaro has partnered with Bio-Techne Corporation (NASDAQ: TECH) for manufacturing and global kit distribution
- Scaled kit production planned to enable clinical laboratories to conduct 10M tests per month beginning July

Background to the antibody test

RenalytixAI, Inc. and Mount Sinai today announce the formation of Kantaro, a Mount Sinai venture, to develop and scale production and distribution of a test kit based on the Mount Sinai-developed high-performance serologic assay for SARS-CoV-2 antibodies. Kantaro has partnered with Minneapolis-based Bio-Techne Corporation to develop and launch the new kit, with the goal of producing more than ten million patient tests per month by July. The two companies have formed a joint commercialization and distribution team to support the rapid distribution of kits to clinical laboratories in the US and around the world.

Kantaro's SARS-CoV-2 test kits are designed for use in any authorized clinical testing laboratory without the need for proprietary equipment. The technology underlying the kits was created by a team of internationally recognized scientists and clinicians, including members from the Departments of Microbiology and Pathology, Molecular and Cell-Based Medicine within the Icahn School of Medicine at Mount Sinai. The original Mount Sinai test was validated in The Mount Sinai Hospital's Clinical Laboratories, and has been performed on over 30,000 patient samples. The Kantaro test kit, an enzyme-linked immunosorbent assay (ELISA), builds on this test technology and is designed to measure the presence or absence of anti-COVID-19 antibodies in addition to measuring the titer (level) of antibodies a person has produced. The kit will utilize not one, but two virus antigens, the full-length spike protein, and its receptor binding domain, necessary for viral entry into cells.

Mount Sinai developed the underlying assay in response to the critical needs of thousands of patients within the hospital system, including those who were severely ill and could potentially benefit from convalescent plasma for emergency therapy. Mount Sinai was issued an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for clinical testing in its CLIA certified laboratory on April 15th. Kantaro plans to seek EUA for the test kit following final validation.

"Antibody testing will be critical to providing patients and governments the essential information they need to help the world economies reopen and begin to recover from COVID-19," said Florian Krammer, PhD, Professor of Microbiology at the Icahn School of Medicine. "With the launch of Kantaro, we look forward to bringing a kit based on our highly specific and sensitive test to every corner of the globe." The serological assay developed by Dr. Krammer and colleagues for the screening and identification of human SARS-CoV-2 seroconverters was described in a paper published in Nature Medicine on May 12, 2020.

"We believe that this technology has the potential for providing insight into immunity, and we're working intensely to develop a quantitative version," said Carlos Cordon-Cardo, MD, PhD, Irene Heinz Given and John LaPorte Given Professor and Chair of Pathology, Molecular and Cell-Based Medicine at Mount Sinai. "We expect that future findings will be critical to vaccine development and the development of advanced therapeutics." Due to the large

number of COVID-19 patients who have been treated at Mount Sinai, with over 5,000 patients returning home to date, the Mount Sinai technology has been utilized across a large and highly diverse population.

“This technology reflects our commitment to everyone affected by SARS-CoV-2 and to developing tools for effectively combatting this disease,” said Erik Lium, PhD, Executive Vice President and Chief Commercial Innovation Officer at Mount Sinai. “We believe that the rapid development, scaleup and distribution of these kits, based on the highly accurate Mount Sinai assay, can be a cornerstone in the global battle against COVID-19.”

“Diagnostics are a national strategic priority and we are now witnessing unprecedented cooperation between academic medicine and private industry to innovate,” said James McCullough, Chief Executive Officer of Renalytix AI. “Working together there is no doubt we can rapidly and safely advance the science to begin winning the war on COVID.”

Related party transaction

Kantaro has been formed as a joint venture between Mount Sinai and RenalytixAI’s wholly-owned subsidiary, Renalytix AI, Inc., in order to develop and scale production and distribution of COVID-19 antibody test kits.

Kantaro’s founding board members include Erik Lium, PhD, Executive Vice President and Chief Commercial Innovation Officer at Mount Sinai, Niyum Gandhi, Executive Vice President and Chief Population Health Officer at Mount Sinai, and James McCullough, CEO of Renalytix AI. Dr. Lium will serve as Chairman.

Mount Sinai has granted a non-exclusive licence to Kantaro to use certain of its intellectual property in connection with the test kits in return for equity interests in Kantaro and a customary sales royalty. Renalytix AI, Inc. will provide key strategic, regulatory, reimbursement and commercial advice to Kantaro in return for equity interests in Kantaro. Mount Sinai will initially hold 75% of the equity interests in Kantaro with Renalytix AI, Inc. initially holding the remaining 25% of the equity interests. Mount Sinai has the ability to appoint up to three board managers to Kantaro with Renalytix appointing one. The joint venture agreements contain customary provisions, including standard indemnities in the event of third party claims against the parties arising out of negligence or actions unrelated to the joint venture to the extent the losses are not covered by insurance. Both Renalytix, AI Inc. and Mount Sinai will advance initial start-up funding to Kantaro in the form of interest bearing loans. The total quantum of the loans is not of a significant nature.

The entry by Renalytix AI, Inc. into the joint venture together with the associated agreements and obligations contained within them is deemed to be a related party transaction pursuant to AIM Rule 13 as Mount Sinai is a substantial shareholder in the Company. The directors of the Company, excluding Erik Lium and Barbara Murphy, who are not considered to be independent for this purpose on account of their connection with Mount Sinai, having consulted with the Company’s nominated adviser, Stifel, consider the terms of the joint venture to be fair and reasonable insofar as the Company’s shareholders are concerned.

*The person responsible for arranging the release of this announcement on behalf of the Company is
James McCullough, CEO.*

For further information, please contact:

Renalytix AI plc
James McCullough, CEO

www.renalytixai.com
Via Walbrook PR

Stifel (Nominated Adviser & Broker)
Alex Price / Nicholas Moore

Tel: 020 7710 7600

N+1 Singer (Joint Broker)
Aubrey Powell / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)

Tel: 020 7496 3000

Walbrook PR Limited

Paul McManus / Lianne Cawthorne

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Mob: 07980 541 893 / 07584 391 303

About Kantaro BioSciences

Kantaro Biosciences (“Kantaro”), a Mount Sinai Health System venture, is dedicated to ensuring that diagnostic tests for critical health challenges are accessible. The company provides academically rigorous, validated and results-driven diagnostics to advance the wellbeing of people, communities and society. Kantaro specializes in the rapid scaleup of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market. The company is majority owned and controlled by Mount Sinai. For more information, visit www.kantarobio.com.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians are in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit <https://www.mountsinai.org> or find Mount Sinai on Facebook, Twitter and YouTube.

About Renalytix AI

Renalytix AI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com